Dopamine-Loaded Polymer-Drug Conjugates for Potential Synergistic Anti-Cancer Treatment

The combination of dopamine with anticancer drugs can result in enhanced anticancer activity. Polymer-drug conjugates (PDCs) containing anticancer drugs, such as platinum-based drugs, and doxorubicin together with dopamine were prepared. PDCs were characterized followed by in vitro cytotoxicity stud...

Full description

Saved in:

Bibliographic Details
Published in:	Polymer-plastics technology and engineering Vol. 61; no. 9; pp. 1003 - 1020
Main Authors:	Tobeka Naki, Matshe, W, Ubanako, Philemon, Adeyemi, Samson A, Balogun, MO, S Sinha Ray, Choonara, Yahya E, Blessing Atim Aderibigbe
Format:	Journal Article
Language:	English
Published:	New York Taylor & Francis Ltd 13-06-2022
Subjects:	Anticancer properties Conjugates Dopamine Doxorubicin Drugs Polymers
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The combination of dopamine with anticancer drugs can result in enhanced anticancer activity. Polymer-drug conjugates (PDCs) containing anticancer drugs, such as platinum-based drugs, and doxorubicin together with dopamine were prepared. PDCs were characterized followed by in vitro cytotoxicity studies using pheochromocytoma (PC12) cell lines. The particle size analysis revealed the particles sizes of the PDCs in the range of 15.68–179.8 nm with PDI in the range of 0.373–0.687. T3 and T6 displayed promising cytotoxic effects with IC50 values of 5.25 and 11.56 μg/mL when compared to the free drugs (29.65 μg/mL for K2PtCl4 and 14.96 μg/mL for procaine). The findings revealed that combining dopamine with anticancer drugs is a promising approach to develop effective therapeutics for the treatment of cancer.
ISSN:	0360-2559 1525-6111
DOI:	10.1080/25740881.2022.2029895